Tatsuro Fukuhara

7PUBLICATIONS
68CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsCellular nervous systemPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 27, 2026
Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

|Apr 16, 2025
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.

Satoru Miura, Hiroshi Tanaka, Toshihiro Misumi

|Dec 13, 2023
Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.

Miyuki Nomura, Mai Ohuchi, Yoshimi Sakamoto

|Sep 28, 2023
A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety.

Tatsuro Fukuhara, Kazuhiro Imai, Taku Nakagawa

|Sep 09, 2023
Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation.

Kana Watanabe, Ryota Saito, Eisaku Miyauchi

|Nov 25, 2021
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.

Hiroki Izumi, Shingo Matsumoto, Jie Liu

Pageof 2

Frequent Collaborators

2 joint publications

Nobuyuki Tanaka

2 joint publications

Naoki Furuya

2 joint publications

Eisaku Miyauchi

2 joint publications

Shunichi Sugawara